WPP Q3 Revenues Rise; Lifts FY22 LFL Revenue Growth View, Adjusts Margin Forecast

British mass media firm WPP Group Plc (WPP.L,WPPGY) reported Wednesday third-quarter revenue of 3.57 billion pounds, a growth of 10.3 percent on a reported basis from last year, and 2.7 on a like-for-like basis.

Revenue less pass-through costs was 2.99 billion pounds, up 13.1 percent on reported basis and 3.8 percent at LFL basis.

In the top five markets, revenues was up 4.5 percent in USA, up 4.2 percent in UK, and up 10.7 percent in India. Meanwhile, revenues in Germany dropped 8.7 percent, but the growth was 3.3 percent excluding the impact of Covid-related contract in prior year. In China, revenue fell 9 percent.

Looking ahead for fiscal 2022, the company raised guidance for LFL revenue less pass-through costs growth to 6.5 percent to 7.0 percent from previously expected 6 percent to 7 percent. Headline operating margin is now expected to be up 30 basis points to 50 basis points, compared to previous view of up around 50 basis points.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT